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Our previous studies have implicated the Wnt antagonist, sFRP1, as a tumour suppressor gene in advanced colorectal cancer. In this
study, we set out to investigate the relationship between sFRP1 expression and large bowel adenomas, a precursor of colorectal
cancer. The induction of b-catenin/TCF mediated transcription is both a frequent early event in colorectal neoplasia, and a key
downstream effect of wnt growth factor signalling. Lithium treatment of a small bowel mucosal cell line (FHs 74 int) induced sFRP1
within 8h, indicating that this gene is positively regulated by b-catenin, contrasting with the suppression of sFRP1 expression, we saw
previously in advanced colorectal cancers. We therefore investigated a series of 12 adenomas and matched large bowel mucosa
samples. Real-time RT–PCR analysis showed a reduction in sFRP1 expression in all 12 dysplastic lesions (median 485-fold, IQR 120-
to 1500-fold), indicating factors other than b-catenin influence sFRP1 levels. In a second series of 11 adenomas, we identified
methylation of the sFRP1 promotor region in all 11 samples, and this was increased compared with the surrounding normal mucosa
in seven cases. Immunohistochemical analysis using a polyclonal antibody supported these findings, with sFRP1 expression reduced in
many of the adenoma samples examined. sFRP1 staining in normal mucosa adjacent to the dysplastic tissue was also reduced
compared with the normal controls, suggesting that sFRP1 expression may be suppressed in a field of mucosa rather than in individual
cells. This study identifies sFRP1 inactivation at the premalignant stage of colorectal cancer development, indicating that these
pathways may be useful targets for chemoprevention strategies in this common solid tumour.
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Loss of control over b-catenin/TCF-mediated transcription is a
central feature of most colorectal tumours (Morin et al, 1997). Wnt
growth factor signalling can also mobilise b-catenin, but its
relationship with colorectal tumorigenesis remains unclear. We
previously showed (Caldwell et al, 2004) that the secreted Wnt
antagonist sFRP1 is downregulated in most established colorectal
cancers and that this coincides with increased methylation of the
gene. This was confirmed in a separate study (Suzuki et al, 2004),
which also demonstrated similar behaviour in other sFRP family
members.
Inactivation of sFRP1 has now been observed in a wide range of
malignancies, including ovarian (Takada et al, 2004), bladder
(Stoehr et al, 2004), mesothelioma (Lee et al, 2004), breast (Ugolini
et al, 2001; Klopocki et al, 2004), oesophageal (Zou et al, 2005),
prostate (Lodygin et al, 2005) and gastric cancers (Byun et al,
2005).
These effects do not appear to be restricted to the sFRPs,
however, as other secreted antagonists of Wnt signalling behave in
a similar manner. Suppression of WIF-1 expression has been
demonstrated in prostate, breast, lung and bladder cancer
(Wissmann et al, 2003), and this has been attributed to
hypermethylation in lung (Mazieres et al, 2004) and gastrointest-
inal cancers (He et al, 2005; Taniguchi et al, 2005), while DKK-1
expression is also lost in colon cancer (Gonzalez-Sancho et al,
2005).
b-Catenin-dependent Wnt signalling can induce expression of
WIF-1 (He et al, 2005) and DKK-1 (Gonzalez-Sancho et al, 2005),
but this has not been investigated for the sFRPs. It would be
reasonable to expect sFRPs to also be induced in response to
b-catenin, as part of a negative feedback process to desensitise a
cell to prolonged Wnt stimuli, but this has not been investigated.
In colorectal cancer, at least, the high frequency of APC and other
mutations that stabilise b-catenin might, therefore, be expected to
lead to induction of these Wnt antagonists, including the sFRPs, if
they were not suppressed by other mechanisms before the onset of
tumorigenesis. Their frequent downregulation therefore indicates
that soluble Wnt antagonists either act as tumour suppressors
whose expression must be lost at some stage in the development of
a range of tumour types, or that their expression is lost
coincidentally during tumorigenesis.
Aberrant crypt foci (ACFs) may be the earliest detectable stage
of colorectal tumorigenesis, and these have been shown to contain
methylated sFRP1 alleles (Suzuki et al, 2004). This infers that
transcription is suppressed at this early stage, but the precise
relationship between sFRP1 methylation patterns and gene
expression has not been determined and the expression level
cannot be measured in ACFs.
The purpose of this study was to examine the b-catenin
dependence of sFRP1 and determine its expression in early
colorectal tumorigenesis. We investigated the capacity of b-catenin
to regulate sFRP1 transcription in a normal intestinal epithelial cell
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sline and measured its relative expression and methylation in
premalignant colorectal adenomas, the earliest stage of tumori-
genesis where expression can be measured reliably. We have also
complemented these data with immunohistochemical detection of
the sFRP1 protein in a similar adenoma series.
MATERIALS AND METHODS
Lithium treatment of cultured cells
The normal small intestine epithelial cell line FHs 74 Int (ATCC)
was cultured using Hybri-Care medium (ATCC) supplemented
with 1.5gl
 1 sodium bicarbonate and 10% foetal calf serum. Cells
were grown in 6cm dishes and treated with 10mM LiCl or 10mM
KCl as a control. Cells were harvested over a time course of 16h
and RNA, DNA and protein were extracted using TRI reagent
(Sigma, Gillingham, Dorset, UK).
Tumour samples
Two cohorts of sporadic adenoma samples were identified from
our tumour bank for methylation and expression analysis. All
samples were collected from patients over 50 years of age and
without a family history of colorectal cancer. All samples were
collected from the sigmoid colon or the rectum and matched rectal
biopsies were taken at the same procedure (5cm or more from the
tumour site). Samples were collected according to our local ethical
committee regulations, with individual consent from each patient
for molecular studies. Separate ethical approval was given for
analysis of paraffin blocks for protein studies (LREC No. 2003/
277).
Semiquantitative real-time PCR
Total RNA was extracted using TRI reagent (Sigma). First-strand
cDNA was synthesised from 2mg of DNase-treated total RNA using
Ready-To-Go You-Prime First-Strand Beads (Amersham Pharma-
cia Biotech UK Ltd, Little Chalfont, Bucks, UK) and random
hexamers (Promega, Southampton, UK).
Oligonucleotide primers and TaqMan probes were designed
using Primer Expresst, version 1.5 (PE Applied Biosystems,
Cambridge, UK). The primers for sFRP1 (NM_003012) gene
amplification were 50-CCAATCCCACCGAAGCCT and 50-AT
GATGGCCTCAGATTTCAACTC. The sequence for the TaqMan
fluorogenic probe was 50-CAAGCCCCAAGGCACAACGGTG. Data
for the sFRP1 gene were normalised to the epithelial cell-specific
gene keratin 8 (KRT8) (NM_002273). For KRT8, the primers and
probe were 50-GATCGCCACCTACAGGAAGCT, 50-ACTCATGTT
CTGCATCCCAGACT and 50-CCGGCTCTCCTCGCCCTCCA, re-
spectively. The TaqMan Universal PCR Master Mix and the
TaqMan probes were purchased from PE Applied Biosystems.
Primers were obtained from Alta Biosciences, Birmingham, UK
(University of Birmingham). Multiplex PCR amplifications were
performed using an ABI PRISM 7700 Sequence Detector in a final
volume of 25ml. Each reaction contained 12.5mlo f 2 TaqMan
Universal PCR Master Mix (PE Applied Biosystems), 90nM KRT8
and sFRP1 primers, 150nM sFRP1 TaqMan probe and 175nM KRT8
TaqMan probe, 1ml of cDNA sample and water. The thermal
cycling conditions comprised an initial step at 501C for 2min and
951C for 10min, followed by 40 cycles at 951C for 15s and 601C for
1min.
Analysis of promoter methylation status
The method used for DNA modification was essentially that of
Grunau et al (2001). In short, 10mg tRNA (Sigma) was added to
1mg of genomic DNA and made up to 100ml. Freshly prepared
NaOH (Sigma) was added to a final concentration of 0.3 M and the
sample was incubated at 421C for 20min. In total, 1.2ml of 5.2–
5.69 M sodium bisulfite (Sigma), 10mM hydroquinone (Sigma) pH
5 was added, the solution overlaid with mineral oil and incubated
at 551C for 4h. DNA was desalted and re-dissolved into 100mlo f
Tris-Cl pH 8 (Sigma). NaOH was added to a final concentration of
0.3 M and the solution was then incubated at 371C for 20min. The
solution was neutralised, 10mg of tRNA were added and nucleic
acids precipitated with ethanol at –201C overnight. Precipitated
DNA was washed with 70% ethanol, dried and re-suspended in
50mlo f1m M Tris-HCl, pH 8.
Methylation status was analysed using the COBRA (COmbined
Bisulfite Restriction Analysis) method (Xiong and Laird, 1997).
The sFRP1 CpG island region was predicted using CpG plot
(www.ebi.ac.uk). A strong CpG island (island size4100bp, GC
percent450.0, Obs/Exp40.6) was detected within the region
 180bp to þ530bp relative to the transcription start site of the
sFRP1 gene. To analyse this region of the gene for methylation,
PCR primers specific for the bisulfite modified sequence were
designed. The sFRP1 CpG island was amplified using the primers:
sFRP1 COBRA F 50-GGTTAGTAGTTGGGTGTTTTTGTTTA and
sFRP1 COBRA R 50-CCTTACCTTAAAACTTAAAAACTTC. One
two hundred and fiftieth of this product was then used in a
subsequent nested PCR reaction using the primers: sFRP1 COBRA
F-nested 50-TTGGGTGTTTTTGTTTAATAAGAATT and sFRP1
COBRA R-nested 50-AAAACTTATCACACTTAAACATCTC. The
PCR conditions used in both reactions were 941C for 3min; 30
cycles of 941C for 20s, 541C for 30s, 721C for 40s; 721C for 7min
and 35 cycles were used in the nested PCR reaction. PCR products
were incubated with restriction enzyme Taq1 for 2h at 651Ct o
assay for methylation and visualised on a 2% agarose gel. The
COBRA assay for sFRP1 measured the methylation state of the
CpG at position þ454 from the start codon ATG.
Immunohistochemistry
An sFRP1 polyclonal antibody was raised in rabbit using a
synthetic peptide (GPYQSGRFYTKPPQC) corresponding to amino
acids 43–57 of Human sFRP1 (Eurogenetec).
Immunohistochemistry was performed using the streptavidin–
biotin indirect immunoperoxidase method as previously described
(Hardy et al, 2002). Briefly, 5mm sections were dewaxed,
rehydrated and blocked by 10% H2O2 in methanol for 10min.
Sections were incubated overnight at 41C with primary antibodies
recognising b-catenin (clone 14, BD Transduction Laboratories,
Cowley, UK) or sFRP1 at a dilution of 1:300 and 1:1000
respectively. After washing with PBS, sections were incubated
with 1:500 dilution of biotinylated goat anti-mouse/rabbit (Dako,
Ely, UK) for 30min. Serial PBS washing and incubation with
streptavidin-peroxidase conjugate (Dako) was undertaken prior to
incubation with diaminobenzidine tetrahydrochloride (Sigma).
Sections were counterstained with haemalum (BDH), dehydrated,
and then analysed by light microscopy.
Two independent observers (CJ and PT) scored the slides. The
number of tumour cells stained was scored as a percentage of the
total number of cells (average of at least 10 high power fields). The
staining was then reported as strong (450% cells stained),
moderate (10–50%), mild (o10%) or no staining. Any discre-
pancies between the two observers were then reviewed jointly to
reach a final assessment.
RESULTS
Effect of b-catenin stabilisation on sFRP1 mRNA
expression
The transcriptional control of sFRP1 has not been investigated
previously. Since it was possible that the frequent downregulation
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swe observed previously in colorectal cancers could be an outcome
of b-catenin action, we chose to investigate this in Fhs74Int, a non-
neoplastic epithelial cell line derived from the small bowel, as no
normal colon cell lines are available. Lithium chloride is an
inhibitor of GSK3b and its consequent ability to stabilise b-catenin
has been exploited widely to mimic Wnt signalling since this
property was characterised (Klein and Melton, 1996). One
advantage of using lithium is that it acts downstream of the
receptor so, unlike treatment with individual Wnt growth factors,
does not depend on the range of FZDs expressed in the cell.
Cultures were grown to confluence then treated with lithium
chloride and sampled over a 16-h time course. b-Catenin
stabilisation was verified by two approaches. Immunohistochem-
istry showed nuclear b-catenin in cells treated with lithium
chloride for 8 and 48h (result not shown), but not in untreated
control cells. We also investigated transcript levels of NKD1,a
b-catenin-dependent gene (Yan et al, 2001) by both RT–PCR
(Figure 1) and real-time RT–PCR, which showed an increase of
over 100-fold after 8h, confirming induction of b-catenin/TCF
activity. sFRP1 transcripts were also induced significantly, to eight
times after 8h, falling to six-fold at 16h (Figure 1).
These results indicate that rather than suppressing sFRP1
expression, b-catenin/TCF activity is associated with the induction
of sFRP1, consistent with a feedback response restricting the
exposure of a normal cell to a prolonged Wnt growth factor signal.
It is unlikely, therefore, that catenin-mediated transcription is
responsible for the downregulation of sFRP1 expression seen in
colorectal cancer, indicating that this is caused by an independent
event in early colorectal tumorigenesis. Large bowel adenomas are
known to be precursors to the majority of colorectal cancers, and
are associated with b-catenin/TCF signalling. We selected a series
of sporadic, left sided, large bowel adenomatous polyps with
matched normal mucosa for analysis.
sFRP1 mRNA expression by real-time quantitative PCR
In order to determine the level of sFRP1 transcription in early
colorectal tumours, we performed quantitative analysis of sFRP1
mRNA levels, using real-time RT–PCR, in a cohort of 12 adenoma
samples and compared these with expression levels in normal
bowel mucosa sampled from the same patient. The sFRP1
expression levels were compared with cytokeratin 8 (KRT8) gene
expression, providing an epithelial cell-specific marker in order to
control for the influence of variation in stromal and inflammatory
cell components between dysplastic and normal epithelium. The
expression levels of KRT8 were consistent between adenoma
(median Ct value¼20.1, IQR 19.7–20.9) and normal samples
(median Ct value¼20.6, IQR 19.4–21.2).
sFRP1 mRNA expression was downregulated by more than 10-
fold in all 12 adenomas compared with matched normal mucosa
(median 485-fold, IQR 120- to 1500-fold, Figure 2). The clinical
and pathological data from these 12 adenomas were investigated,
but no correlation was found between sFRP1 expression level,
patient sex, tumour size or grade of dysplasia.
These data indicate that sFRP1 expression is widely and
substantially suppressed in premalignant lesions to a level
comparable with that seen in advanced cancers of the large bowel
and implicates suppression of sFRP1 expression in the process of
premalignant colorectal tumorigenesis. Our previous studies
demonstrated that deletion of the sFRP1 gene in early colorectal
tumours is a rare event, and we therefore postulated that
methylation of the promotor region suppresses expression, as we
have previously identified to be the case in advanced colorectal
cancer.
Hypermethylation of the sFRP1 promotor region in
colorectal adenoma DNA
To investigate epigenetic changes in the promotor region of sFRP1
in premalignant colorectal lesions, a second cohort of 11 adenoma
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Figure 1 Real-time PCR quantitation of sFRP1 expression levels in a
normal cell line following treatment with LiCl. (A) Real-time PCR
quantitation of relative sFRP1 mRNA expression measured across a series
of time points following lithium chloride treatment of the normal cell line
FHS 74 Int according to the comparative CT method. The initial step in the
calculations is the normalisation of the sFRP1 gene to the KRT8 gene in
order to normalise quantity and quality of the cDNA samples. The level of
sFRP1 expression at each time point was then normalised to the level of
sFRP1 expression before treatment. sFRP1 mRNA levels increased upon
LiCl treatment peaking with an eight-fold increase at 8h, which fell to six-
fold at 16h. (B) RT–PCR results for hNKD1 and b-actin at time 0 and
16h.
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Figure 2 Real-time PCR quantitation of relative sFRP1 mRNA
expression in a series of 12 matched colorectal adenoma samples. Real-
time RT–PCR was performed and the level of sFRP1 expression in each
adenoma sample was compared to the results obtained for the adjacent
matched normal tissue. The sFRP1 values are shown on a logarithmic scale.
In all 12 adenoma samples, the sFRP1 mRNA levels were reduced
substantially (410 fold) with 83% of the samples showing a reduction of
more than a 100-fold.
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ssamples, with matched normal mucosa was selected for analysis by
COBRA (COmbined Bisulfite Restriction Analysis) (Xiong and
Laird, 1997). This assay measured the methylation state of the CpG
at position þ454 from the start codon of sFRP1. Methylation was
detected in all 11 adenoma samples (Figure 3, median 45%, IQR
35–60%) and hypermethylation of the adenoma, compared with
the matched normal mucosa, was seen in seven out of 11 samples.
The percentage methylation was unchanged in two matched
samples and was reduced in two samples compared to matched
normal mucosa. Overall, the level of methylation was higher in
adenomas (median 45%) than in normals (median of 25%, IQR-
10–50%).
Since the completion of these experiments Suzuki et al (2004)
have reported sFRP1 promotor hypermethylation in ACFs from
large bowel mucosa. That sFRP1 is hypermethylated in both of
these lesions lends weight to the hypothesis that ACFs are indeed
precursors of large bowel adenomas.
Immunohistochemical analysis of sFRP1 protein
expression and cellular distribution
To assess how the expression changes were reflected in the protein
level and distribution, we raised a rabbit polyclonal antibody using
a synthetic peptide (GPYQSGRFYTKPPQC) corresponding to
amino acids 43–57 of human sFRP1. The specificity of the
antibody was analysed against HEK293 cells, transiently trans-
fected with mouse sFRP1 by Western blotting. The antibody gave a
single band at 37kD in the transfected HEK293 cell line but no
band in untransfected cells (Figure 4).
sFRP1 protein expression and cellular distribution were
analysed in a series of formalin-fixed wax-embedded sections
taken from seven non-neoplastic large bowel mucosa samples and
22 left sided colorectal adenomas. All of the normal sections
stained for sFRP1, four moderately (10–50% of the cells stained)
and three strongly (450% of cells stained). Staining was
predominantly in the cytoplasm, and localised to the supranuclear
region in both the normal and dysplastic mucosa. Cells stained
uniformly at the base and apices of the crypts in normal
epithelium.
In contrast to the normal control samples, only nine out of 22
adenoma sections showed moderate staining (10–50% of the
tumour cells stained), with three out of 22 demonstrating strong
staining (450% of tumour stained). There was no apparent
staining for sFRP1 in five of the adenomas and a further five
adenomas showed only mild staining (up to 10% of the tumour
cells stained) (Table 1). This represented a reduction in sFRP1
protein expression in at least 45% of these benign adenomas
compared with matched controls.
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Figure 3 sFRP1 methylation status was analysed using the COBRA
(COmbined Bisulfite Restriction Analysis) method as described previously
(Caldwell et al, 2004). Methylated DNA remains capable of cleavage while
unmethylated DNA is resistant. In total, 11 matched colorectal adenoma
samples were analysed. The percentage of methylated DNA in each
sample was measured by comparing the intensity of the ‘cut’ band against
that of the ‘uncut’ band.
Figure 4 Immunohistochemistry and Western blot analysis using a Polyclonal sFRP1 antibody. (A) A Western blot containing lysate from HEK293 cells
transiently transfected with full-length mouse sFRP1 and untransfected HEK293 cells was probed an sFRP1 antibody raised in rabbit. The antibody gavea
single band at 37kDa in the transfected HEK293 cell line (b) but no band in untransfected cell (a). (B) The same antibody was used to analyse sFRP1 protein
expression and cellular distribution in a series of formalin fixed wax embedded sections taken from normal bowel mucosa and colorectal adenomas. All of
the normal sections showed moderate to strong cytoplasmic, supranuclear staining (a and b) whereas 45% (10 out of 22) of the adenomas demonstrated
either no staining (c) or mild staining (d).
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adenoma in all 22 cases. There was a notable reduction in sFRP1
expression in these normal crypts compared with the normal (non-
neoplastic) control samples (N¼7) used in our IHC study,
suggesting there may be a field change in sFRP1 expression. This
may also explain why higher levels of methylation were observed
in the matched normal mucosa in this study than we had
previously identified in normal mucosa from patients with
advanced cancers (Caldwell et al, 2004), which are usually sampled
at a greater distance from the neoplasm.
DISCUSSION
We have shown that sFRP1 transcription can be driven by
b-catenin in normal intestinal epithelial cells, but that premalig-
nant colorectal adenomas contain greatly reduced levels of sFRP1
compared to matched normal mucosa and this is accompanied by
increased methylation at the sFRP1 locus. Immunohistochemistry
with an antibody raised against sFRP1 detected a mostly
cytoplasmic signal, which was reduced in adenomas.
In our experiments, lithium chloride treatment stabilised
b-catenin and induced sFRP1 transcription, consistent with a
negative feedback loop whose physiological role would be to
antagonise a strong or persistent WNT signal. This parallels
previous data for WIF-1 (He et al, 2005) and DKK-1 (Gonzalez-
Sancho et al, 2005), and infers that colorectal tumours should
express high levels of all three classes of Wnt antagonists as a
result of the b-catenin stabilising mutations normally present.
In our adenoma series, however, sFRP1 mRNA levels were
reduced by a median factor of 485-fold compared with matched
normal mucosa. This corresponds to the pattern we observed
previously for sFRP1 in established colorectal cancers (Caldwell
et al, 2004), indicating that expression is suppressed by another,
dominant, mechanism. Another similarity with cancers was the
common hypermethylation of the sFRP1 locus in adenomas and it
is likely that this contributes to the reduction in transcription we
observed.
Our COBRA assay provides an indirect measure of the degree of
methylation at the sFRP1 locus, but does not necessarily relate
directly to functional suppression of the gene. A previous study
(Suzuki et al, 2004) surveyed the region around the 50 end of sFRP1
by bisulphite sequencing. Although this showed an association
between the degree of methylation and downregulation of
transcription in cancers, it did not reveal a direct relationship
between expression levels and methylation of any specific CpG
sites. This is likely to prove complex and a more extensive study
will be required before it is possible to predict the degree of
expression from an sFRP1 allele bearing any given methylation
pattern.
The consistently high degree of sFRP1 downregulation revealed
by our real-time RT–PCR study and the high frequency of
hypermethylation, we observed indicate that these changes are well
established at an early stage of tumorigenesis, and the similar
effects we reported previously in cancers (Caldwell et al, 2004) are
unlikely to be the result of genetic change during progression.
Analysis of sFRP1 protein expression by immunohistochemistry
gave a less consistent picture than our RNA analysis. One
disadvantage of analysing premalignant adenomas is the relatively
small size of the sample, which restricts the range of analyses that
can be performed and we were unable to compare RNA and
protein detection on the same adenoma samples. In normal
mucosa, our antibody detected a cytoplasmic signal that appeared,
at higher resolution, to be concentrated in a supra-nuclear region
that could be the Golgi apparatus. Since sFRP1 is a secreted
protein, we expected to stain the cell membrane, but a study using
an independent anti-sFRP1 antibody found a similar distribution
to ours in the epithelial cells of colonic crypts (Oberschmid et al,
2004). This, and our control experiments, indicates that the
staining is specific. In contrast, however, a recent study detected
sFRP1 transcripts in the underlying mesenchymal cells, and not
the epithelium, by in situ hybridisation (Gregorieff et al, 2005).
The reasons for this difference are not clear, but the mesenchymal
signal was lost upon tumorigenesis, in agreement with our, and
other, mRNA studies.
Immunohistochemical analysis of adenomas indicated a reduc-
tion in protein expression, but not the consistent downregulation
we saw by real-time RT–PCR. This may be a matter of sampling,
since these analyses were performed on different series of
adenomas or it may reflect essential differences between these
approaches: Real-time RT–PCR is a quantitative, albeit relative,
analysis while immunohistochemical protocols are designed for
sensitivity and show very poor relationships between the level of
target protein and the signal obtained. Immunofluorescence may
provide a more proportional signal, but this cannot be performed
on paraffin embedded specimens, which were the only form
available to us in this study.
The frequent downregulation of sFRP1, and other Wnt
antagonists (Gonzalez-Sancho et al, 2005; He et al, 2005), in
colorectal carcinogenesis infers that tumour cells retain a
requirement for Wnt signalling despite containing high levels of
b-catenin and the reason for this is not clear at present. Re-
expression of sFRP1 in the colorectal cancer cell line HCT116 led
to a reduction in nuclear b-catenin (Suzuki et al, 2004), while
inhibition of WNT1 signalling by a function-blocking antibody
caused apoptosis in primary colorectal cancer cells and cell lines
(He et al, 2005). It appears, therefore, that expression of any of a
number of soluble Wnt antagonists might lead to apoptosis and
tumour cells must suppress expression of these to survive. It is also
plausible that b-catenin independent outcomes of Wnt signalling
contribute to tumour progression. For example, WNT2 dependent,
sFRP1 sensitive, activation of c-jun/AP-1 contributes to cell
invasion (Le Floch et al, 2005), which may explain the requirement
for c-jun action in intestinal tumorigenesis in mice (Nateri et al,
2005).
The current data on Wnt antagonists in colorectal cancer
indicate that their methylation and inactivation may occur before
APC action is lost, and two independent studies in mice are
consistent with this. First, inactivation of DNA methyltransferases
prevented colorectal tumour formation in APC min mice (Eads
et al, 2002), indicating that methylation of at least some loci is
essential for tumorigenesis. Second, inactivation of APC in the
Table 1 Results of immunohistochemistry on seven normal bowel
mucosa and 22 adenoma samples (TA¼tubular adenoma; TVA¼tubular
villous adenoma)
sFRP1 staining
Sample characteristics None Mild Moderate Strong Total
Normal 00 4 3 7
Adenoma
Histology
TA 1 3 5 0 9
TVA 4 2 4 3 13
Size
p9mm 2 3 5 2 12
X10mm 3 2 4 1 10
Dysplasia
Mild 4 2 5 3 14
Moderate 1 2 3 0 6
Severe 0 1 1 0 2
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apoptosis throughout the crypts (Sansom et al, 2004) and it is
possible that one cause of this is induction of soluble Wnt
antagonists in the absence of hypermethylation, blocking Wnt
action.
If this interpretation is correct, soluble Wnt antagonists may
prove to be effective targets in the chemoprevention of colorectal
cancer, as preventing their methylation or causing their re-
expression should lead to apoptosis in tumour cells. The apparent
requirement for the tumour to suppress members of each of three
groups of soluble Wnt antagonists indicates that it may only be
necessary to restore the expression of a single species to obtain a
therapeutically useful effect.
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